$VXRT
Vaxart, Inc.

2021 Q3 Form 10-Q Financial Statement

#000143774921018764 Filed on August 05, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2021 Q2 2020 Q2
Revenue $200.0K $112.0K $523.0K
YoY Change -24.53% -78.59% 515.29%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.042M $5.150M $3.900M
YoY Change 20.33% 32.05% 182.61%
% of Gross Profit
Research & Development $12.41M $10.74M $5.114M
YoY Change 168.83% 109.95% 37.96%
% of Gross Profit
Depreciation & Amortization $211.0K $120.0K $25.00K
YoY Change 520.59% 380.0% -80.0%
% of Gross Profit
Operating Expenses $17.45M $15.89M $9.049M
YoY Change 122.19% 75.57% 78.06%
Operating Profit -$17.25M -$15.78M -$8.526M
YoY Change 127.32% 85.02% 70.62%
Interest Expense $26.00K $23.00K
YoY Change
% of Operating Profit
Other Income/Expense, Net -$337.0K -$334.0K -$425.0K
YoY Change -28.3% -21.41% -32.22%
Pretax Income -$17.56M -$16.09M -$8.951M
YoY Change 117.92% 79.71% 59.16%
Income Tax $21.00K $30.00K $26.00K
% Of Pretax Income
Net Earnings -$17.58M -$16.12M -$8.977M
YoY Change 117.48% 79.53% 59.25%
Net Earnings / Revenue -8791.5% -14389.29% -1716.44%
Basic Earnings Per Share -$0.14 -$0.13
Diluted Earnings Per Share -$141.8K -$133.3K -$120.2K
COMMON SHARES
Basic Shares Outstanding 122.8M 120.9M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q3 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $187.7M $184.6M $44.40M
YoY Change 40.68% 315.73% 172.39%
Cash & Equivalents $167.2M $165.3M $44.39M
Short-Term Investments $20.44M $19.32M
Other Short-Term Assets $4.441M $4.801M $900.0K
YoY Change 161.24% 433.44% 12.5%
Inventory
Prepaid Expenses
Receivables $190.0K $107.0K $227.0K
Other Receivables $0.00
Total Short-Term Assets $192.3M $189.5M $45.73M
YoY Change 41.82% 314.41% 167.29%
LONG-TERM ASSETS
Property, Plant & Equipment $5.427M $4.339M $345.0K
YoY Change 719.79% 1157.68% -77.26%
Goodwill
YoY Change
Intangibles $14.06M $14.50M $16.23M
YoY Change -10.97% -10.67% -9.64%
Long-Term Investments $16.28M $14.34M
YoY Change
Other Assets $828.0K $371.0K $137.0K
YoY Change 1050.0% 170.8% 34.31%
Total Long-Term Assets $48.84M $39.35M $18.46M
YoY Change 155.43% 113.13% -8.34%
TOTAL ASSETS
Total Short-Term Assets $192.3M $189.5M $45.73M
Total Long-Term Assets $48.84M $39.35M $18.46M
Total Assets $241.1M $228.8M $64.19M
YoY Change 55.86% 256.51% 72.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.745M $3.702M $1.166M
YoY Change 100.16% 217.5% 91.15%
Accrued Expenses $4.387M $4.137M $6.378M
YoY Change 17.8% -35.14% 329.49%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $3.100M $3.200M $3.200M
YoY Change 3.33% 0.0% 88.24%
Total Short-Term Liabilities $12.60M $12.78M $11.50M
YoY Change 22.26% 11.15% 53.78%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $156.0K $142.0K $18.00K
YoY Change 688.89% 0.0%
Total Long-Term Liabilities $156.0K $142.0K $18.00K
YoY Change 688.89% 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.60M $12.78M $11.50M
Total Long-Term Liabilities $156.0K $142.0K $18.00K
Total Liabilities $36.19M $29.06M $23.96M
YoY Change 57.12% 21.32% 11.91%
SHAREHOLDERS EQUITY
Retained Earnings -$198.6M -$181.0M -$126.9M
YoY Change 47.08% 42.6% 20.9%
Common Stock $403.5M $380.8M $167.2M
YoY Change 51.31% 127.79% 38.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $204.9M $199.8M $40.24M
YoY Change
Total Liabilities & Shareholders Equity $241.1M $228.8M $64.19M
YoY Change 55.86% 256.51% 72.32%

Cashflow Statement

Concept 2021 Q3 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$17.58M -$16.12M -$8.977M
YoY Change 117.48% 79.53% 59.25%
Depreciation, Depletion And Amortization $211.0K $120.0K $25.00K
YoY Change 520.59% 380.0% -80.0%
Cash From Operating Activities -$14.27M -$13.16M -$520.0K
YoY Change 54.24% 2430.96% 62.5%
INVESTING ACTIVITIES
Capital Expenditures -$1.324M -$2.198M -$10.00K
YoY Change 327.1% 21880.0% -93.75%
Acquisitions
YoY Change
Other Investing Activities -$3.088M -$13.75M $0.00
YoY Change
Cash From Investing Activities -$4.412M -$15.95M -$10.00K
YoY Change 1323.23% 159380.0% -93.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 20.64M 37.07M 15.06M
YoY Change -79.07% 146.12% 81.23%
NET CHANGE
Cash From Operating Activities -14.27M -13.16M -520.0K
Cash From Investing Activities -4.412M -15.95M -10.00K
Cash From Financing Activities 20.64M 37.07M 15.06M
Net Change In Cash 1.965M 7.956M 14.53M
YoY Change -97.79% -45.24% 85.57%
FREE CASH FLOW
Cash From Operating Activities -$14.27M -$13.16M -$520.0K
Capital Expenditures -$1.324M -$2.198M -$10.00K
Free Cash Flow -$12.94M -$10.96M -$510.0K
YoY Change 44.78% 2049.61% 218.75%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
122814467
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
122814467
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
110271093
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
122818085
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
110271093
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
1824000 USD
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
5006000 USD
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
1278000 USD
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0 USD
CY2021Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0 USD
vxrt Impairment Of Property And Equipment
ImpairmentOfPropertyAndEquipment
0 USD
CY2021Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
433000 USD
CY2020Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
433000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
866000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
866000 USD
CY2020Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
0 USD
CY2021Q2 vxrt Contract With Customer Asset Revenue Recognized
ContractWithCustomerAssetRevenueRecognized
0 USD
CY2021Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
0 USD
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
0 USD
CY2021Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
0 USD
CY2021Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2021Q2 vxrt Lessee Finance Lease Number Of Leases
LesseeFinanceLeaseNumberOfLeases
0 pure
us-gaap Longterm Purchase Commitment Period
LongtermPurchaseCommitmentPeriod
P30M
us-gaap Dilutive Securities
DilutiveSecurities
0 USD
CY2020Q2 us-gaap Dilutive Securities
DilutiveSecurities
0 USD
us-gaap Dilutive Securities
DilutiveSecurities
0 USD
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
165266000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
126870000 USD
CY2021Q2 us-gaap Short Term Investments
ShortTermInvestments
19318000 USD
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
0 USD
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
107000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
334000 USD
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4801000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1327000 USD
CY2021Q2 us-gaap Assets Current
AssetsCurrent
189492000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
128531000 USD
CY2021Q2 us-gaap Long Term Investments
LongTermInvestments
14339000 USD
CY2020Q4 us-gaap Long Term Investments
LongTermInvestments
0 USD
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4339000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1480000 USD
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5808000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6838000 USD
CY2021Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
14495000 USD
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
15361000 USD
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
371000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
372000 USD
CY2021Q2 us-gaap Assets
Assets
228844000 USD
CY2020Q4 us-gaap Assets
Assets
152582000 USD
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3702000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2133000 USD
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1791000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2052000 USD
CY2021Q2 vxrt Liability Related To Sale Of Future Royalties Current
LiabilityRelatedToSaleOfFutureRoyaltiesCurrent
3150000 USD
CY2020Q4 vxrt Liability Related To Sale Of Future Royalties Current
LiabilityRelatedToSaleOfFutureRoyaltiesCurrent
2779000 USD
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4137000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4799000 USD
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
12780000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11763000 USD
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4363000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5156000 USD
CY2021Q2 vxrt Liability Related To Sale Of Future Royalties Noncurrent
LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent
11777000 USD
CY2020Q4 vxrt Liability Related To Sale Of Future Royalties Noncurrent
LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent
12150000 USD
CY2021Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
142000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
109000 USD
CY2021Q2 us-gaap Liabilities
Liabilities
29062000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
29178000 USD
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
12000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
11000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-8977000 USD
us-gaap Net Income Loss
NetIncomeLoss
-32123000 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.27
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
380783000 USD
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
272274000 USD
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-181004000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-148881000 USD
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-9000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
199782000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
123404000 USD
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
228844000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
152582000 USD
CY2021Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
112000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
523000 USD
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
618000 USD
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
3425000 USD
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10737000 USD
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5114000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20810000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6656000 USD
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5150000 USD
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3896000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11094000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5886000 USD
CY2021Q2 us-gaap Restructuring Charges
RestructuringCharges
0 USD
CY2020Q2 us-gaap Restructuring Charges
RestructuringCharges
39000 USD
us-gaap Restructuring Charges
RestructuringCharges
0 USD
us-gaap Restructuring Charges
RestructuringCharges
103000 USD
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
15887000 USD
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
9049000 USD
us-gaap Operating Expenses
OperatingExpenses
31904000 USD
us-gaap Operating Expenses
OperatingExpenses
12645000 USD
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-15775000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8526000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-31286000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-9220000 USD
CY2021Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
23000 USD
CY2020Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
23000 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
32000 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
64000 USD
CY2021Q2 vxrt Noncash Interest Expense On Liability
NoncashInterestExpenseOnLiability
334000 USD
CY2020Q2 vxrt Noncash Interest Expense On Liability
NoncashInterestExpenseOnLiability
446000 USD
vxrt Noncash Interest Expense On Liability
NoncashInterestExpenseOnLiability
800000 USD
vxrt Noncash Interest Expense On Liability
NoncashInterestExpenseOnLiability
937000 USD
CY2021Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
0 USD
CY2020Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2000 USD
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1000 USD
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2000 USD
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-16086000 USD
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-8951000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-32055000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-10095000 USD
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
30000 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
26000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
68000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
179000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-16116000 USD
us-gaap Net Income Loss
NetIncomeLoss
-10274000 USD
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
us-gaap Net Income Loss
NetIncomeLoss
-10274000 USD
CY2021Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-4000 USD
CY2020Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
0 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-9000 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
0 USD
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16120000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8977000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32132000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10274000 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
120925570
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
67676138
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-16116000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-8977000 USD
us-gaap Net Income Loss
NetIncomeLoss
-32123000 USD
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
74675131
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
118174099
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
176235000 USD
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
36202000 USD
CY2021Q2 vxrt Stock Issued During Period Value Exercise Of Common Stock Warrants
StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants
200000 USD
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
661000 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2604000 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-4000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-16116000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
199782000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
123404000 USD
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
101914000 USD
vxrt Stock Issued During Period Value Exercise Of Common Stock Warrants
StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants
1849000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
892000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3855000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-9000 USD
us-gaap Net Income Loss
NetIncomeLoss
-32123000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
199782000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
31293000 USD
CY2020Q2 vxrt Stock Issued During Period Value Exercise Of Common Stock Warrants
StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants
14309000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
98000 USD
CY2020Q2 vxrt Adjustments To Additional Paid In Capital Disgorgement Of Shortswing Profits Net Of Costs
AdjustmentsToAdditionalPaidInCapitalDisgorgementOfShortswingProfitsNetOfCosts
652000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2860000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-8977000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
40235000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
12952000 USD
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
8722000 USD
vxrt Stock Issued During Period Value Exercise Of Common Stock Warrants
StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants
24658000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
116000 USD
vxrt Adjustments To Additional Paid In Capital Disgorgement Of Shortswing Profits Net Of Costs
AdjustmentsToAdditionalPaidInCapitalDisgorgementOfShortswingProfitsNetOfCosts
652000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2956000 USD
us-gaap Net Income Loss
NetIncomeLoss
-10274000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
40235000 USD
us-gaap Net Income Loss
NetIncomeLoss
-32123000 USD
us-gaap Net Income Loss
NetIncomeLoss
-10274000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1989000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1193000 USD
us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
24000 USD
us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
0 USD
us-gaap Share Based Compensation
ShareBasedCompensation
3855000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
2956000 USD
vxrt Noncash Interest Expense On Liability
NoncashInterestExpenseOnLiability
800000 USD
vxrt Noncash Interest Expense On Liability
NoncashInterestExpenseOnLiability
937000 USD
vxrt Noncash Revenue Related To Sale Of Future Royalties
NoncashRevenueRelatedToSaleOfFutureRoyalties
802000 USD
vxrt Noncash Revenue Related To Sale Of Future Royalties
NoncashRevenueRelatedToSaleOfFutureRoyalties
2800000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-227000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3392000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3473000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
657000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1348000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
148000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1596000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1376000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29751000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3729000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2818000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
3000 USD
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
34890000 USD
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
-0 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
1200000 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-36508000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10000 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1849000 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
24658000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
892000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
116000 USD
vxrt Proceeds From Disgorgement Of Shortswing Profits Net Of Costs
ProceedsFromDisgorgementOfShortswingProfitsNetOfCosts
0 USD
vxrt Proceeds From Disgorgement Of Shortswing Profits Net Of Costs
ProceedsFromDisgorgementOfShortswingProfitsNetOfCosts
652000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
104655000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
34601000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
38396000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
30862000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
126870000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13526000 USD
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
165266000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
44388000 USD
vxrt Issuance Of Warrants To Placement Agents Designees
IssuanceOfWarrantsToPlacementAgentsDesignees
0 USD
vxrt Issuance Of Warrants To Placement Agents Designees
IssuanceOfWarrantsToPlacementAgentsDesignees
453000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
56000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
vxrt Leaserelated Assets And Liabilities Derecognized On Early Termination And Modification Of Leases
LeaserelatedAssetsAndLiabilitiesDerecognizedOnEarlyTerminationAndModificationOfLeases
158000 USD
vxrt Leaserelated Assets And Liabilities Derecognized On Early Termination And Modification Of Leases
LeaserelatedAssetsAndLiabilitiesDerecognizedOnEarlyTerminationAndModificationOfLeases
0 USD
us-gaap Noncash Or Part Noncash Acquisition Value Of Assets Acquired1
NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
314000 USD
us-gaap Noncash Or Part Noncash Acquisition Value Of Assets Acquired1
NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
170000 USD
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 pure
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
0 USD
CY2020Q4 us-gaap Long Term Investments
LongTermInvestments
0 USD
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5107000 USD
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2053000 USD
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
768000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
573000 USD
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b>Use of Estimates</b> – The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities in the financial statements and accompanying notes. Actual results and outcomes could differ from these estimates and assumptions.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b>Concentration of Credit Risk</b> – Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash, cash equivalents, available-for-sale investments and accounts receivable. The Company places its cash, cash equivalents and available-for-sale investments at financial institutions that management believes are of high credit quality. The Company is exposed to credit risk in the event of default by the financial institutions holding the cash and cash equivalents to the extent such amounts are in excess of the federally insured limits. The Company has <em style="font: inherit;">not</em> experienced any losses on its deposits since inception.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The primary focus of the Company’s investment strategy is to preserve capital and meet liquidity requirements. The Company’s investment policy addresses the level of credit exposure by limiting the concentration in any <em style="font: inherit;">one</em> corporate issuer or sector and establishing a minimum allowable credit rating. The Company generally requires <em style="font: inherit;">no</em> collateral from its customers.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p>
CY2021Q2 us-gaap Investments And Cash
InvestmentsAndCash
198932000 USD
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
9000 USD
CY2021Q2 vxrt Investments And Cash Fair Value Disclosure
InvestmentsAndCashFairValueDisclosure
198923000 USD
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
165266000 USD
CY2021Q2 us-gaap Short Term Investments
ShortTermInvestments
19318000 USD
CY2021Q2 us-gaap Long Term Investments
LongTermInvestments
14339000 USD
CY2020Q4 us-gaap Investments And Cash
InvestmentsAndCash
126870000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
-0 USD
CY2020Q4 vxrt Investments And Cash Fair Value Disclosure
InvestmentsAndCashFairValueDisclosure
126870000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
126870000 USD
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4339000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1480000 USD
CY2021Q2 us-gaap Depreciation
Depreciation
120000 USD
CY2020Q2 us-gaap Depreciation
Depreciation
25000 USD
us-gaap Depreciation
Depreciation
195000 USD
us-gaap Depreciation
Depreciation
44000 USD
vxrt Impairment Of Property And Equipment
ImpairmentOfPropertyAndEquipment
0 USD
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5808000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6838000 USD
CY2021Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
20380000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
20380000 USD
CY2021Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
5885000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
5019000 USD
CY2021Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
14495000 USD
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
15361000 USD
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
866000 USD
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1731000 USD
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1732000 USD
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1732000 USD
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1731000 USD
CY2021Q2 vxrt Finitelived Intangible Asset Expected Amortization After Year Four
FinitelivedIntangibleAssetExpectedAmortizationAfterYearFour
6703000 USD
CY2021Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
14495000 USD
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1508000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1618000 USD
CY2021Q2 vxrt Accrued Clinical And Manufacturing Expenses Current
AccruedClinicalAndManufacturingExpensesCurrent
1175000 USD
CY2020Q4 vxrt Accrued Clinical And Manufacturing Expenses Current
AccruedClinicalAndManufacturingExpensesCurrent
1772000 USD
CY2021Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1060000 USD
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
777000 USD
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
394000 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
632000 USD
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4137000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4799000 USD
CY2021Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
0 USD
CY2020Q4 vxrt Contract With Customer Asset Revenue Recognized
ContractWithCustomerAssetRevenueRecognized
219000 USD
CY2020Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
13000 USD
CY2021Q2 us-gaap Sublease Income
SubleaseIncome
-0 USD
CY2020Q2 us-gaap Sublease Income
SubleaseIncome
55000 USD
us-gaap Sublease Income
SubleaseIncome
36000 USD
us-gaap Sublease Income
SubleaseIncome
109000 USD
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0978 pure
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y9M21D
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1060000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1986000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1585000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1641000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1113000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
7385000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1231000 USD
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
6154000 USD
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1791000 USD
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4363000 USD
CY2021Q2 us-gaap Short Term Lease Commitment Amount
ShortTermLeaseCommitmentAmount
23000 USD
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
511000 USD
CY2020Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
212000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
1173000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
401000 USD
CY2021Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
71000 USD
CY2020Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
3000 USD
us-gaap Short Term Lease Cost
ShortTermLeaseCost
131000 USD
us-gaap Short Term Lease Cost
ShortTermLeaseCost
6000 USD
CY2021Q2 us-gaap Variable Lease Cost
VariableLeaseCost
331000 USD
CY2020Q2 us-gaap Variable Lease Cost
VariableLeaseCost
13000 USD
us-gaap Variable Lease Cost
VariableLeaseCost
624000 USD
us-gaap Variable Lease Cost
VariableLeaseCost
24000 USD
CY2021Q2 us-gaap Lease Cost
LeaseCost
913000 USD
CY2020Q2 us-gaap Lease Cost
LeaseCost
173000 USD
us-gaap Lease Cost
LeaseCost
1892000 USD
us-gaap Lease Cost
LeaseCost
322000 USD
CY2021Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
886000 USD
CY2020Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
237000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
1820000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
474000 USD
CY2021Q2 us-gaap Purchase Obligation
PurchaseObligation
28900000 USD
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
us-gaap Dividends
Dividends
0 USD
CY2021Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
16550706
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
9288870
CY2021Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
232434
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1230863
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6813033
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.70
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
8900000
vxrt Share Based Compensation Arrangement By Share Based Payment Award Shares Available For Grant Decrease From Grants
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantDecreaseFromGrants
2515088
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2515088
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.52
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
571926
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.56
vxrt Share Based Compensation Arrangement By Share Based Payment Award Forfeited
ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeited
416817
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
436554
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.94
vxrt Share Based Compensation Arrangement By Share Based Payment Award Canceled
ShareBasedCompensationArrangementByShareBasedPaymentAwardCanceled
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
33961
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
8.01
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
8032592
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8285680
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.96
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8285680
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.96
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y5M4D
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
30100000 USD
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3485798
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
2.52
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y2M4D
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
18100000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
892000 USD
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
571926
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3200000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
116000 USD
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
178381
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
524000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-16116000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-8977000 USD
us-gaap Net Income Loss
NetIncomeLoss
-32123000 USD
us-gaap Net Income Loss
NetIncomeLoss
-10274000 USD
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
120925570
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
74675131
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
118174099
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
67676138
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.27
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
CY2021Q2 us-gaap Dilutive Securities
DilutiveSecurities
0 USD
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8123363
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26588035
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7973194
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
31169834

Files In Submission

Name View Source Status
0001437749-21-018764-index-headers.html Edgar Link pending
0001437749-21-018764-index.html Edgar Link pending
0001437749-21-018764.txt Edgar Link pending
0001437749-21-018764-xbrl.zip Edgar Link pending
ex_252214.htm Edgar Link pending
ex_252215.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
pipelineqone.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vxrt-20210630.xsd Edgar Link pending
vxrt-20210630_cal.xml Edgar Link unprocessable
vxrt-20210630_def.xml Edgar Link unprocessable
vxrt-20210630_lab.xml Edgar Link unprocessable
vxrt-20210630_pre.xml Edgar Link unprocessable
vxrt20210630_10q.htm Edgar Link pending
vxrt20210630_10q_htm.xml Edgar Link completed